Kamada (KMDA) - Total Liabilities

Latest as of September 2025: ILA111.98 Million ILA ≈ $300.21K USD

Based on the latest financial reports, Kamada (KMDA) has total liabilities worth ILA111.98 Million ILA (≈ $300.21K USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.

Kamada - Total Liabilities Trend (2006–2024)

This chart illustrates how Kamada's total liabilities have evolved over time, based on quarterly financial data. See Kamada working capital to net assets to evaluate short-term liquidity relative to the company's equity base.

Kamada Competitors by Total Liabilities

The table below lists competitors of Kamada ranked by their total liabilities.

Company Country Total Liabilities
GemVax&KAEL Co.Ltd
KQ:082270
Korea ₩101.65 Billion
Suzhou Mingzhi Technology Co. Ltd. A
SHG:688355
China CN¥319.92 Million
Bijou Brigitte modische Accessoires Aktiengesellschaft
XETRA:BIJ
Germany €169.97 Million
Mobiltel Iletisim Hizmetleri Sanayi ve Ticaret AS
IS:MOBTL
Turkey TL3.83 Billion
AMTD Digital Inc.
NYSE:HKD
USA $351.62 Million
BTS Group AB (publ)
ST:BTS-B
Sweden Skr1.59 Billion
Yem Chio Co Ltd
TW:4306
Taiwan NT$24.02 Billion

Liability Composition Analysis (2006–2024)

This chart breaks down Kamada's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see KMDA market cap overview.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 4.03 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.42 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.30 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Kamada's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Kamada (2006–2024)

The table below shows the annual total liabilities of Kamada from 2006 to 2024.

Year Total Liabilities Change
2024-12-31 ILA112.79 Million
≈ $302.39K
+1.72%
2023-12-31 ILA110.89 Million
≈ $297.28K
-24.24%
2022-12-31 ILA146.36 Million
≈ $392.38K
+3.18%
2021-12-31 ILA141.84 Million
≈ $380.28K
+342.89%
2020-12-31 ILA32.03 Million
≈ $85.86K
-16.77%
2019-12-31 ILA38.48 Million
≈ $103.16K
+49.49%
2018-12-31 ILA25.74 Million
≈ $69.01K
-21.09%
2017-12-31 ILA32.62 Million
≈ $87.45K
-1.02%
2016-12-31 ILA32.95 Million
≈ $88.35K
+11.76%
2015-12-31 ILA29.48 Million
≈ $79.05K
-23.66%
2014-12-31 ILA38.62 Million
≈ $103.55K
-21.83%
2013-12-31 ILA49.41 Million
≈ $132.46K
-18.63%
2012-12-31 ILA60.72 Million
≈ $162.79K
-3.27%
2011-12-31 ILA62.78 Million
≈ $168.30K
-3.47%
2010-12-31 ILA65.03 Million
≈ $174.36K
+98.51%
2009-12-31 ILA32.76 Million
≈ $87.83K
+11.36%
2008-12-31 ILA29.42 Million
≈ $78.87K
-48.56%
2007-12-31 ILA57.19 Million
≈ $153.32K
+33.60%
2006-12-31 ILA42.80 Million
≈ $114.76K
--

About Kamada

TA:KMDA Israel Drug Manufacturers - Specialty & Generic
Market Cap
$331.09 Million
ILA123.50 Billion ILA
Market Cap Rank
#14473 Global
#165 in Israel
Share Price
ILA2141.00
Change (1 day)
-2.06%
52-Week Range
ILA2123.00 - ILA2870.00
All Time High
ILA3940.00
About

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its products include KAMRAB/KEDRAB indicated as prophylaxis of rabies; CYTOGAM for prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmuniza… Read more